Advertisement
MCP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/mcp.M600259-MCP200 on March 5, 2007.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M600259-MCP200v1
M600259-MCP200v2
6/6/1088    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagnato, C.
Right arrow Articles by Han, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagnato, C.
Right arrow Articles by Han, D. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Molecular & Cellular Proteomics 6:1088-1102, 2007.
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

Research

Proteomics Analysis of Human Coronary Atherosclerotic Plaque

A Feasibility Study of Direct Tissue Proteomics by Liquid Chromatography and Tandem Mass Spectrometry*,S

Carolina Bagnato{ddagger},§, Jaykumar Thumar{ddagger},§, Viveka Mayya{ddagger}, Sun-Il Hwang{ddagger}, Henry Zebroski, Kevin P. Claffey{ddagger}, Christian Haudenschild||, Jimmy K. Eng**, Deborah H. Lundgren{ddagger} and David K. Han{ddagger},{ddagger}{ddagger}

From the {ddagger} Department of Cell Biology, Center for Vascular Biology, University of Connecticut School of Medicine, Farmington, Connecticut 06030, Proteomics Resource Center, Rockefeller University, New York, New York 10021, || Holland Laboratories, American Red Cross, Rockville, Maryland 20855, and ** Fred Hutchinson Cancer Research Center, Seattle, Washington 98109


   ABSTRACT
TOP
 ABSTRACT
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cardiovascular disease presents significant variations in human populations with respect to the atherosclerotic plaque progression, inflammation, thrombosis, and rupture. To gain a more comprehensive picture of the pathogenic mechanism of atherosclerosis and the variations seen in patients, efficient methods to identify proteins from the normal and diseased arteries need to be developed. To accomplish this goal, we tested the feasibility and efficiency of protein identification by a recently developed method, termed direct tissue proteomics (DTP). We analyzed frozen and paraformaldehyde-fixed archival coronary arteries with the DTP method. We also validated the distinct expression of four proteins by immunohistochemistry. In addition, we demonstrated the compatibility of the DTP method with laser capture microdissection and the possibility of monitoring specific cytokines and growth factors by the absolute quantification of abundance method. Major findings from this feasibility study are that 1) DTP can be used to efficiently identify proteins from paraformaldehyde-fixed, paraffin-embedded, and frozen coronary arteries; 2) approximately twice the number of proteins were identified from the frozen sections when compared with the paraformaldehyde-fixed sections; 3) laser capture microdissection is compatible with DTP; and 4) detection of low abundance cytokines and growth factors in the coronary arteries required selective reaction monitoring experiments coupled to absolute quantification of abundance. The analysis of 35 human coronary atherosclerotic samples allowed identification of a total of 806 proteins. The present study provides the first large scale proteomics map of human coronary atherosclerotic plaques.

Atherosclerosis is a disease of blood vessels presenting a wide spectrum of pathological manifestations ranging from simple thickening and narrowing of the blood vessels to catastrophic coronary arterial occlusion and myocardial infarction. Approximately 61 million Americans, almost one-quarter of the population, have some form of cardiovascular disease. Acute coronary syndromes and cerebrovascular stroke, the principal components of vascular diseases, are the first and third leading causes of death in the United States, accounting for more than 40% of all deaths (Centers for Disease Control statistics). To develop effective antiatherosclerotic interventions, it is critically important to understand the pathological mechanism of atherosclerotic vascular disease.

Multiple cell types are present in the atherosclerotic plaque, and the proteins from these cells are likely to contribute to the pathogenesis of atherosclerosis. Many proteins expressed in macrophages, vascular smooth muscle cells (SMCs),1 and inflammatory cells, such as growth factors, connective tissue constituents, pro- and anticoagulants, lipid-associated proteins, metabolic regulators, and tissue enzymes have all been implicated in the complex process of atherogenesis. Therefore, careful analysis of proteins within the atherosclerotic vascular tissue will provide a repertoire of proteins that participate in vascular remodeling and atherogenesis. As a first step, the identification of the human atherosclerotic proteome will serve as a foundation for further studies to generate new hypotheses and to test these hypotheses.

The proteome is defined as all proteins expressed in a cell, tissue, or organism. According to this, proteomics is defined as the systematic analysis of proteins for identification, quantification, post-translational modifications, subcellular localization, protein-protein interactions, and enzymatic activities (1). Since the early 1990s, proteomics techniques using mass spectrometry coupled to chromatographic separation have been significantly improved and applied to the study of increasingly complex biological systems (2–4). The availability of human and other protein databases and bioinformatics tools now allows large scale studies where thousands of proteins can be analyzed simultaneously. In addition, laser capture microdissection (LCM) technology has emerged as a powerful technique to isolate specific areas or cell types within a tissue section, a critical method for refining tissue proteomics profiling (5–7). Although these proteomics approaches are becoming commonly available to many investigators, their application to human atherosclerosis has not been carried out to date.

In this study, we utilized the recently described paraffin-embedded tissue (DTP) method (8) to test the feasibility of protein identification in human coronary vessels with various stages of atherosclerosis. Proteins identified by tandem mass spectrometry were carefully analyzed and classified. Many of these proteins have been implicated previously in atherosclerosis development; however, most of them have not been observed in human coronary atherosclerotic lesions. These proteins include some interesting factors and known regulatory proteins, such as pigment-epithelium derived factor (PEDF), periostin, milk fat globule-EGF-factor 8 (MFG-E8), and annexin I, all of which were validated by in situ immunohistochemistry (IHC). This study explored the most efficient way to analyze protein identification from human coronary arteries and atherosclerotic plaques. Our findings suggest that large scale protein profiling using frozen coronary artery samples represents the most efficient method for sample processing in terms of protein identification. Furthermore we demonstrated that LCM coupled to the shotgun proteomics technique is feasible. We also demonstrated that detection and quantification of low abundance growth factors and cytokines is possible by combining selective reaction monitoring mass spectrometry with AQUA.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials
Histology reagents, hematoxylin, eosin, and mounting media were from Thermo Finnigan (Pittsburg, PA). All HPLC grade solvents, hydrogen peroxide, and polylysine-coated slides as well as microscope glass coverslips were purchased from Fisher. Microcentrifuge tubes and metal rim slides for LCM were provided by Molecular Machines & Industries (Knoxville, TN). Antibodies utilized for IHC were as follows: Ham-56 (DakoCytomation, Carpinteria, CA), {alpha}-actin (Sigma), PEDF (Chemicon, Temecula, CA), periostin (Abcam, Cambridge, MA), MFG-E8 (R&D Systems, Minneapolis, MN), and annexin I (Santa Cruz Biotechnology, Santa Cruz, CA). The ABC kit, secondary antibodies (biotinylated horseradish peroxidase conjugates), and diaminobenzidine (DAB) system for IHC development were purchased from Vector Laboratories (Burlingame, CA). The TUNEL assay kit was from Roche Applied Science.

Human Coronary Tissue
Archival samples of 35 coronary vessels in paraffin or frozen blocks, obtained from 28 patients undergoing cardiac transplant, were approved for the protein identification study by the Institutional Review Board as deidentified samples. Paraffin blocks (25 vessels) and optimal cutting temperature blocks (10 vessels) consisted of left anterior descending (25 samples), right coronary artery (six samples), and circumflex coronary artery (four samples). The tissue blocks were cut as 5- or 10-µm sections and processed for either direct trypsin digestion, LCM analysis followed by direct trypsin digestion, or SDS-PAGE followed by in-gel trypsin digestion.

Histopathological Examination and Tissue Classification
Each paraffin and frozen block was cut in 5-µm-thick serial sections. Samples were stained with hematoxylin and eosin (H&E) and for IHC using standard protocols. IHC with Ham-56 (macrophage marker) and {alpha}-actin (SMC marker) were used to characterize and classify each vessel according to American Heart Association guidelines for histopathological classification. Atherosclerotic lesions were classified into three histological categories: early, intermediate, and advanced.

Human Atherosclerotic Coronary Artery Mass Spectrometry Analysis
Sample Preparation from DTP—
Serial tissue sections (5-µm thickness) were scraped from slides, and the tissue was collected in microcentrifuge tubes. Samples were suspended and boiled in 30% ACN and 100 mM ammonium bicarbonate (NH4HCO3) buffer for 10 min to reverse the cross-linking of proteins induced by formalin fixation (8). Proteins were digested with trypsin (12 ng/µl) at 37 °C overnight, and supernatant was collected after centrifugation for 10 min at 16,000 x g acceleration. Peptides were dried in SpeedVac, resuspended in buffer A (5% ACN, 0.4% acetic acid, 0.005% heptafluorobutyric acid (HFBA) in water), and analyzed by LC-MS/MS.

Sample Preparation from Frozen (Optimal Cutting Temperature) Embedded Tissue (In-gel Trypsin Digestion)—
The tissue from serial sections (10-µm thickness) was scraped from the slides and collected in microcentrifuge tubes. Samples were either digested and analyzed directly as described above or extracted in RIPA buffer (150 mM NaCl, 10 mM tris, 0.1% SDS, 1% Triton, 1% deoxycholate, 5 mM EDTA, protease inhibitor) and homogenized by ultrasonication. Protein gel electrophoresis (SDS-PAGE) was performed using 100 µg of tissue lysate, and protein bands were visualized by staining gels with Coomassie Blue dye. After fixation and destaining, gel bands were cut, and in-gel trypsin digestion was performed as described previously (9). Samples were resuspended in buffer A and analyzed by LC-MS/MS.

Sample Preparation from Tissue Obtained by LCM—
The LCM microscope, including the laser system, was purchased from Molecular Machines & Industries (Geneva, Switzerland). Histological information (H&E and IHC) from serial sections was used to identify different regions that were cut and pooled from multiple sections and analyzed to obtain area-specific proteomics information. Tissue sections from paraffin and frozen blocks were processed on special membrane slides with a metal rim. Specific areas were cut using an ultraviolet laser, and the tissue was collected on caps of specially designed microcentrifuge tubes. Samples were suspended in 30% ACN, 100 mM NH4HCO3 buffer; boiled for 10 min; and subjected to in-solution trypsin digestion (12 ng/µl at 37 °C overnight). Peptides obtained from LCM experiments were resuspended in buffer A and analyzed by LC-MS/MS.

Liquid Chromatography and Tandem Mass Spectrometry
All the samples were analyzed on an LTQ (a two-dimensional ion trap) instrument equipped with a commercial nanospray source (Thermo Finnigan, San Jose, CA). Samples were loaded by a microautosampler (Famos, LC Packings, Sunnyvale, CA) onto an 11-cm x 100-µm fused silica capillary column packed with reverse C18 material (5-µm, 100-Å Magic beads, Michrom Bioresources, Auburn, CA). The solvent system was delivered by an HP1100 pump (Agilent Technologies, Palo Alto, CA). Peptides were eluted with a gradient from 100% buffer A to 80% buffer B (0.4% acetic acid, 0.005% HFBA in ACN) in 105 min. Each survey scan was followed by five MS/MS scans of the most intense ions. Dynamic exclusion features were enabled to maximize the fragmentation of less abundant peptide ions. Sample loading, solvent delivery, and scan function were controlled by the Xcalibur software (Thermo Finnigan).

Bioinformatics Data Processing and Analysis
A total of 327 LC-MS/MS runs were searched against a non-redundant human protein database concatenated to its reversed database (Advanced Biomedical Computing Center, December 1, 2004) using the SEQUEST algorithm (10). Searching parameters included mass tolerance of ±1.5 Da, trypsin specificity, and differential methionine oxidation. SEQUEST results were automatically submitted to PeptideProphet for probability calculation. The generated data set was filtered using INTERACT based on the following criteria: {Delta}Cn ≥ 0.1, Xcorr: +1, ≥1.9; +2, ≥2.2; +3, ≥3.7. Those proteins that were identified based on the presence of one peptide only were excluded during data filtering and analysis using the INTERACT software. These criteria were adjusted and selected based on reversed database search and analysis of false positive rate (the resultant false positive rate for proteins was 2.2%).

Detection and Quantification of Stromal Cell-derived Factor 1 {alpha} (SDF1-{alpha}) and Growth Factors in Human Atherosclerotic Coronary Artery Samples
SDF1-{alpha} and growth factors in the atherosclerotic human coronary arteries were detected and quantified by using a technique termed AQUA (11). The AQUA methodology consists of selection of a suitable tryptic peptide as a unique identifier of the protein of interest and the addition of the synthetic heavy isotope-labeled counterpart as an internal standard for quantification by mass spectrometry (see Fig. 3A). The methodology was implemented as described previously (12). The standard peptides and the product ions chosen for quantification of SDF1-{alpha} and the growth factors by liquid chromatography multiple reaction monitoring (MRM) are detailed in Supplemental Table 1. Amine-protected (Fmoc (N-(9-fluorenyl)methoxycarbonyl)) and heavy isotope (13C5,15N)-labeled amino acids (valine and proline) were procured from Isotec (St. Louis, MO). The standard peptides were synthesized at the Rockefeller University Proteomics Resource Center. Isotope-labeled AQUA standard peptides were synthesized using an Intavis MultiPep parallel peptide synthesizer (Intavis, Koln, Germany) at the 5-µmol scale. An optimum chromatographic method was developed for acquiring the data in a multiplexed manner. Proteins from frozen sections of atherosclerotic human coronary arteries were extracted using the RIPA buffer supplemented with 0.2% SDS. 100-µg quantities of the frozen tissue protein extract were resolved by SDS-PAGE. Gel bands below 30 kDa were excised and subjected to in-gel trypsin digestion in the presence of ~1000 fmol of the AQUA standard peptides. The solvent used for dissolving the tryptic peptide mixtures was supplemented with 0.01% hydrogen peroxide and 5% formic acid to oxidize the methionine residues to their sulfoxide version.


Figure 3
View larger version (31K):
[in this window]
[in a new window]

  		FIG. 3. Detection and quantification of the cytokines/growth factors in the atherosclerotic human coronary arteries. Schematic diagram of the AQUA methodology used for the detection of selected cytokines/growth factors is shown in A and B. Synthesized stable isotope-labeled peptides act as internal standards for the quantification of endogenous peptides derived from the tissue sections. 100-µg quantities of frozen tissue protein extract were used for the detection of the cytokines and growth factors. Multiple reaction monitoring chromatograms corresponding to the standard peptides (red) and the endogenous peptides (blue) selected for quantifying SDF1-{alpha}, unprocessed TGF-ß1, basic fibroblast growth factor (FGF), and PDGF-ß are shown in C. Absolute quantities of SDF1-{alpha} and unprocessed TGF-ß1 were found to be in low femtomole amounts, and fibroblast growth factor and PDGF-ß were below the detection limit. Quantities of SDF1-{alpha} and TGF-ß1 were found to be 27.2 and 167.6 pg, respectively, in 100 µg of coronary artery lysate.

 
Immunohistochemistry
For histological examination and classification of the tissue samples, H&E staining was performed according to standard procedures. The identification of specific cell populations within the plaque (i.e. macrophages and SMCs) was performed by antigen-specific immunostaining. IHC was performed with the use of the VECTASTAIN ABC system (Vector Laboratories). Sections were sequentially blocked with 3% H2O2, 5% normal serum (Vector Laboratories) matching the host of the secondary antibody, and avidin/biotin blocking solution (Vector Laboratories) for 30 min at room temperature. Annexin I staining was performed with antigen retrieval in 10 mM sodium citrate, 0.05% Tween 20, pH 6 buffer. Primary antibodies against human Ham-56 (1:50, mouse monoclonal) from DakoCytomation, {alpha}-actin (1:1000, mouse monoclonal) from Sigma, PEDF (1:200, mouse monoclonal) from Chemicon, periostin (1:100 rabbit polyclonal) from Abcam, MFG-E8 (1:50, monoclonal) from R&D Systems, and annexin I (1:100, rabbit polyclonal) from Santa Cruz Biotechnology were used for immunostaining. Secondary antibodies (horse anti-mouse and goat anti-rabbit) were used at 1:200 dilutions. Sections were developed by DAB substrate (Vector Laboratories) and counterstained with hematoxylin for microscopic visualization.

Apoptosis Assay
To evaluate the extent of apoptosis in the plaque, TUNEL assay was performed by using an in situ cell death detection kit (Roche Applied Science). We followed the manufacturer's protocol with minor modifications. Briefly tissue sections were deparaffinized and blocked for endogenous peroxidase activity (3% hydrogen peroxide in water) for 30 min at room temperature. Samples were treated with proteinase K (20 µg/ml) for 30 min at room temperature. Positive controls were treated with DNase I (1 µg/ml) for 10 min at room temperature. Terminal DNA labeling was performed at 37 °C for 1 h with a reaction mixture containing fluorescein-conjugated nucleotides and terminal deoxynucleotidyltransferase enzyme. As a negative control, the enzyme was excluded during incubation. Samples were blocked with 2% BSA for 30 min at room temperature and treated with a horseradish peroxidase-conjugated antibody against fluorescein deoxynucleotides (30 min at 37 °C). Finally the reaction was visualized with a DAB system.


   RESULTS
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Proteome Analysis of Human Atherosclerotic Coronary Arteries—
To gain insights into the biology of atherosclerosis, we applied a recently developed methodology, termed DTP, that allows protein identification directly from formalin-fixed, paraffin-embedded tissue samples (8). This method was developed and optimized using commercially available prostate cancer paraffin-embedded tissue arrays. A number of critical issues could not be addressed in the first study: 1) the efficiency of protein identification in paraformaldehyde-fixed, paraffin-embedded human coronary artery samples when compared with fresh frozen samples, 2) the efficiency of protein identification when the DTP method is compared with SDS-PAGE gel separation and in-gel digestion method, and 3) compatibility of LCM with the DTP method. Moreover given the limited availability of human coronary artery tissue samples in either paraformaldehyde-fixed or frozen preparations, we wanted to assess the best method to analyze these samples to maximize protein identification using LC-MS/MS technologies. In addition, because every tissue type contains various quantities of highly abundant proteins, extracellular matrix material, and lipids, we tested the feasibility and efficiency of protein identification in human coronary atherosclerotic lesions.

The overall strategy of this study is outlined in Fig. 1. Tissues from two different sources (frozen or paraffin tissue blocks) were processed in three ways (Fig. 1, A–C) for protein extraction and trypsin proteolysis as described under "Experimental Procedures": A, total section deparaffinization and in-solution trypsin digestion; B, LCM of specific target areas in frozen or paraffin sections; and C, SDS-PAGE protein separation and in-gel trypsin digestion of frozen tissues. Tryptic peptides were separated by liquid chromatography and fragmented in the mass spectrometer by the process of CID (13). The resulting mass spectra were interpreted automatically by running the SEQUEST algorithm against the human protein database containing {approx}56,709 entries. Combined data obtained from the three different sample treatments gave a total number of 2211 unique proteins including the identification of 1405 single peptide-matched proteins. After excluding the proteins identified based on single peptides we identified 806 unique proteins with high confidence.


Figure 1
View larger version (28K):
[in this window]
[in a new window]

  		FIG. 1. Schematic diagram representing the overall proteomics approaches of this study. Three different strategies (A, B, and C) utilized for the proteome analysis of human atherosclerotic arteries are shown. Samples from different sources were processed, and extracted proteins were digested with trypsin. Resulting peptides were analyzed by LC-MS/MS for protein identification. A tandem mass spectrum with the prominent b- and y-ions series of one representative peptide from the analyzed sample is shown in the lower panel.

 
We next compared the efficiency of protein identification from the three different strategies used (Fig. 1, A–C). The comparison of the number of identified proteins between similar quantities of starting coronary artery sections from frozen or paraformaldehyde-fixed tissues revealed that more than double the number of proteins was identified from fresh frozen samples (Table I). Although we utilized a total of 125-µm thickness of the coronary artery sections with similar lesion types, we identified 225 proteins from the paraformaldehyde-fixed samples as multiple peptide hits, whereas 558 proteins were identified from the frozen sections. Supplemental Tables 2 and 3 list all of the identified proteins, the number of peptides and the independently identified peptides by tandem mass spectrometry, and other relevant information important for peptide and protein identification. From these results, we conclude that our strategy of proteomics profiling from frozen sections yielded significantly better proteome coverage because it identified at least twice the number of proteins identified from paraffin-embedded sections.


View this table:
[in this window]
[in a new window]

  		TABLE I Summary of protein identification from human atherosclerotic arteries

A summary of the numbers of the proteins identified during the application of the three strategies used for tissue proteomics analysis is shown. The first and second columns indicate the tissue source (frozen or paraffin blocks) and the approach used for tissue processing.

 
In addition, we tested the feasibility of protein identification from the LCM samples by mass spectrometry. In this procedure, tissue sections were first mounted on a polymer membrane followed by weak hematoxylin staining, laser dissection, and collection of the dissected tissue using commercially available microcentrifuge caps with a sticky surface. We were concerned about the efficiency of protein extraction from the polymer membranes as well as the extraction of undesired hydrophobic polymer ions that could potentially interfere with LC-MS/MS. Another reason for performing LCM was to possibly overcome the presence of high abundance extracellular matrix proteins that could overwhelm the low abundance proteins. As shown in Fig. 2A, using the Molecular Machines & Industries system, we were able to efficiently microdissect and capture the whole intima (top row), the remaining tunica media containing mainly vascular SMCs (middle row), and the tunica adventitia (bottom row). The flow diagram in Fig. 2B shows the general procedure by which 15 samples were analyzed. Using this procedure, we identified 495 multihit proteins, indicating that LCM is compatible with the DTP strategy using LC-MS/MS. Because the laser-dissected tissue sections were selected from regions where macrophages, endothelial cells, or vascular SMCs were enriched, we could not directly compare the protein identification obtained by this approach with the results obtained with the previously described strategies. The proteins identified by LCM-selected areas are available as supplemental data (Supplemental Table 4, intima hyperplasia; Supplemental Table 5, media; Supplemental Table 6, adventitia).


Figure 2
View larger version (39K):
[in this window]
[in a new window]

  		FIG. 2. Laser capture microdissection and protein identification procedure. A, representative pictures for intima hyperplasia, media, and adventitia of a coronary artery selected, laser-microdissected, and captured for proteome analysis. Upper, middle, and bottom panels show the sequence of microdissection, first capturing the tunica intima (top row), second capturing the tunica media (middle row), and finally capturing the tunica adventitia (bottom row). B, schematic flow diagram of sample processing after the LCM; a total of 55 independent LC-MS/MS experiments were performed during samples analysis.

 
Feasibility of Detection of Selected Cytokines/Growth Factors in Human Coronary Atherosclerotic Plaques—
When we examined the total list of 806 identified proteins from human atherosclerotic plaques, we did not find known growth factors and cytokines attributed previously to the migration and proliferation of vascular and inflammatory cells. Thus, we wanted to test whether we could detect and quantify some of these important mediators by using more selective mass spectrometry and proteomics techniques. One such technique, termed AQUA, combined with MRM has been used in the laboratory previously (12). In this technique, a standard tryptic peptide representing the protein of interest is synthesized in the presence of heavy isotope-labeled amino acids, and the absolute quantity of the endogenous peptide is measured by direct comparison of the chromatographic peak area with that of the standard (Fig. 3B). We synthesized four heavy isotope-labeled standard peptides for the following cytokines/growth factors: transforming growth factor ß (TGF-ß), basic fibroblast growth factor, platelet-derived growth factor ß (PDGF-ß), and SDF1-{alpha} (Supplemental Table 1). As shown in Fig. 3C, we could successfully detect SDF1-{alpha} and TGF-ß from whole coronary artery tissue lysate after 1D gel protein resolution. These results indicate that the combination of efficient protein extraction (0.2% SDS buffer), reduction of sample complexity (1D gel electrophoresis), and a more selective and sensitive technique allows the detection of low abundance cytokines present in the coronary tissue. This strategy represents an additional tool for the specific qualitative and quantitative analysis of these types of factors that could not be identified by the shotgun proteomics approaches.

Analysis of Proteins Likely to Be Involved in Atherogenesis: Known Factors and Other Proteins Not Implicated Previously in the Context of the Disease—
Proteomics analyses of human coronary atheroma resulted in the identification of many different types of proteins. Some of these are known to participate in atherosclerosis development, whereas others might be implicated in the progression of the disease but have not been identified in the atheroma by the currently available methods. Our goal was to validate a reasonable number of proteins identified by the proteomics analysis as well as to gain biological insight into the potential function of these proteins in atherogenesis. Toward this goal, we carefully analyzed our entire list of 806 proteins in the context of the published literature and selected four groups of proteins for further analysis: 1) extracellular matrix proteins, 2) lipid-binding and metabolism-associated proteins, 3) inflammation-related proteins, and 4) apoptotic-cell phagocytic ligands and receptors. Supplemental Table 7 shows the proteins selected to be included in these categories from the main list of 806 identified proteins. Although some of the factors are not directly related to atherosclerosis, evidence of their known function from the literature and their presence in the atherosclerotic lesions could be an indication that they may have a functional role in atherogenesis. To validate mass spectrometry-based protein identification, IHC was performed using 5–22 human coronary artery samples. The specimens were selected for the presence of regions that demonstrated histological hallmarks of human coronary atherosclerotic plaques, including macrophage foam cells, intima SMCs, fibrous caps, inflammatory angiogenic regions, cholesterol clefts with necrotic core, adventitial inflammation, and medial atrophy. Most of the coronary arteries selected contained several of these characteristics of atherosclerosis and, therefore, allowed us to validate protein expression from multiple coronary artery samples. Four proteins were selected from the main list of 806 proteins for further validation using immunohistochemical analysis.

Validation of a Proinflammatory Factor and an Extracellular Matrix Protein Expression in Atherosclerotic Coronary Arteries—
Macrophage infiltration and inflammation are characteristic features of atherosclerotic lesion progression. To validate protein detection and identification by mass spectrometry, we selected one of the proteins involved in inflammation/angiogenesis and explored its expression by IHC. PEDF is a member of the serine/protease inhibitor family that has a known neurotrophic activity (14). We selected PEDF as a target for validation and examined the expression of this protein in the context of the atherosclerotic plaque. To define the cells in the coronary arteries, we utilized an anti-{alpha}-smooth muscle actin antibody for vascular SMCs and a Ham-56 antibody for detecting macrophage foam cells and endothelial cells. As shown in Fig. 4, A–C, low power magnification of a human coronary atherosclerotic plaque stained for H&E (A) showed strong positive staining for PEDF in macrophage-derived foam cells (C). Higher power magnification of adjacent sections stained for PEDF and macrophages revealed that lipid-loaded macrophage foam cells are strongly positive for PEDF (Fig. 4, A'–C'). PEDF antibody also stained the inflammatory angiogenic areas present in the intima (Fig. 5, A and B, and Supplemental Fig. S1). Interestingly staining for PEDF was very weak or absent in coronary arteries with diffused intima thickening, indicating that medial SMCs from normal coronary arteries have very little or no PEDF expression (Supplemental Fig. S2, A–D) and that the expression of the factor is associated with the infiltration of the intima with inflammatory cells and the development of intima hyperplasia. In support of this idea, anti-PEDF antibody stained strongly the intima of preatheroma lesions that were also positive for Ham-56 staining (Supplemental Fig. S3). Positive staining was also observed in highly inflammatory areas within the adventitia that were also positive for Ham-56 (Fig. 5, C, D, E, and F). The specificity of anti-PEDF antibody was tested by omitting the primary antibody and by including the isotype-matched non-immune IgG as controls that do not show staining (Supplemental Figs. S1, C and D, and S2, E and F). These IHC images are representative of 22 stained atheroma lesions for PEDF expression. Of the total 22 cases studied by IHC, 15 (68%) showed variable levels of macrophage and inflammatory infiltration coincident with Ham-56 and PEDF staining. In contrast, 7 of 22 (32%), most demonstrating histological features of diffuse, non-inflammatory intima thickening, were all negative for PEDF. These results indicate that proteomics identification of PEDF in coronary arteries can be validated by using IHC.


Figure 4
View larger version (140K):
[in this window]
[in a new window]

  		FIG. 4. Validation of pigment epithelium-derived factor identification by mass spectrometry: positive staining in the luminal macrophage-derived foam cells in the atheroma. Low power magnifications (4x) of an H&E-stained coronary artery section (A), macrophage marker Ham-56-stained section (B), and PEDF-stained section (C) are shown in the top panel. Higher magnification images (20x) of the selected areas marked with a dashed rectangle are shown in A', B', and C' (middle panel). The small "dash" at the bottom in A, B, and C shows the atrophied media. PEDF staining of foam cells of an early preatheroma lesion is shown in D (4x), E (20x), and F (40x). IH, intima hyperplasia; I, intima; L, lumen; M, media.

 

Figure 5
View larger version (157K):
[in this window]
[in a new window]

  		FIG. 5. Validation of pigment epithelium-derived factor identification by mass spectrometry: positive areas in the intima and adventitia. Co-distribution of Ham-56 (A) and PEDF (B) staining in the intima and immunohistological characterization of inflammatory cells in the adventitia are shown. Low (C, 4x) and high (D, 20x) power magnification of an H&E image show inflammatory areas in the adventitia. Ham-56 (E) and PEDF (F) adventitia inflammatory stained areas are shown at high power magnification (20x). I, intima; IH, intima hyperplasia; M, media; Ad., adventitia.

 
Extracellular matrix proteins, including proteoglycans as well as glycoproteins, are known to be expressed at increased levels during the progression of atherosclerosis. Proteomics profiling with mass spectrometry allowed the identification of many of these factors (listed in Supplemental Table 7), including a protein identified as periostin. Although periostin has been shown to be induced in a rat carotid balloon injury and restenosis model (15), the expression of periostin in human atherosclerosis has not been examined to date. This prompted us to analyze periostin expression together with cell identification markers in human coronary atherosclerotic plaques. As shown in Fig. 6, periostin is distributed mainly in the intima as it can be confirmed based on Ham-56 and {alpha}-actin staining. As shown in Supplemental Fig. S4, we were able to confirm this pattern of staining; anti-periostin antibody stains the intima of an intermediate lesion with the atheroma in progress (foam cells, large amount of extracellular matrix deposition, and an incipient necrotic core). This sample shows how periostin expression decreased toward the area of intima-media transition (Supplemental Fig. S4, B and C, label decreased in the direction of the dashed arrows). On the other hand, advanced lesions presenting calcification show that anti-periostin antibody stains areas adjacent to the calcified core and the atrophied media (Supplemental Fig. S5). Negative controls for periostin staining where the primary antibody was excluded are shown in Supplemental Figs. S4D and S5D. Periostin expression was tested in 11 samples, many of them with advanced complicated lesions with different levels of calcifications. Eight of the samples (73%) were positive for periostin staining. The three negative samples (27%) presented diffuse intima thickening without excess core calcifications and advanced inflammatory areas.


Figure 6
View larger version (195K):
[in this window]
[in a new window]

  		FIG. 6. Validation of periostin expression in an advanced atherosclerotic lesion. A, B, and C, 4x images of periostin, Ham-56, and {alpha}-actin immunostaining are shown in the top row. D, E, and F, 20x images of the selected areas in the dashed squares are shown in the middle row. G, H, and I, 20x images showing the selected areas in the rectangles from the top row are shown in the bottom panel. Note that periostin staining is mainly in the intima (A) and overlaps with a subset of Ham-56-positive macrophages and {alpha}-actin-positive SMCs (arrows and higher magnification images in G, H, and J). L, lumen; M, media.

 
Engulfment Ligands Are Present in Human Atherosclerotic Plaques—
Apoptosis of vascular and inflammatory cells has been implicated in the pathophysiology of atherosclerosis (16) particularly during the rupture of the atherosclerotic plaque (17, 18). It has been proposed that during atheroma progression endothelial cells, SMCs, and macrophages are exposed to factors that induce apoptosis, turning the plaque from a stable lesion to a vulnerable, unstable, and inflammatory tissue. As part of the apoptosis process, phagocytosis of apoptotic cells is essential to clear cell debris and avoid excess production and secretion of proinflammatory cytokines (19, 20). Although the contribution of macrophages seems to be critical in animal models of atheroma progression (21), the protective or contributory role for phagocytosis of apoptotic cells during atherosclerosis progression has not been well defined. Supporting data suggest that impaired phagocytosis of apoptotic cells promotes disease development (22, 23). In this context we decided to analyze the expression of proteins specifically associated with the phagocytosis of apoptotic cells, including phagocytic receptors as well as bridging molecules required for engulfment. A list of these proteins is available in Supplemental Table 7. MFG-E8 and annexin I were selected to validate their mass spectrometry identification by using IHC. In Fig. 7, vessel staining by MFG-E8 antibody demonstrates that the protein is mainly expressed in the intima, consistent with areas that also stain for the macrophage marker Ham-56 (Fig. 7, A and B). This staining pattern is better appreciated at higher magnification in Fig. 7, D and E. The MFG-E8 antibody also stains areas that implicate migratory SMCs in the tunica intima. Supporting this, Fig. 7 (F and G) shows an area in the intima clearly positive for both MFG-E8 and {alpha}-actin staining, denoting the presence of SMCs in the MFG-E8-positive area. Overall a subset of macrophages that are positive for Ham-56 are also positive for MFG-E8, whereas there is a macrophage population that is clearly negative for MFG-E8 (Fig. 7, D and E). Similar results were also found for vascular SMCs when serial sections were analyzed for MFG-E8 and {alpha}-actin (Fig. 7, F and G). The MFG-E8 expression profile was confirmed by staining five different coronary arteries. One representative example of MFG-E8 staining is shown in Supplemental Fig. S6. We found that this particular sample represents an advanced and complex lesion where the lumen has been occluded and later reorganized. Therefore, it was possible to test multiple areas rich in SMCs as well as foam cells especially in the disrupted intima. MFG-E8 antibody stains foam cells in the area surrounding the remaining lumen that are clearly negative for {alpha}-actin (Supplemental Fig. S7, C and D). Among the five different coronary arteries that were stained for MFG-E8, four of them (80%) are clearly positive, whereas one sample presenting diffuse intima thickening showed no staining.


Figure 7
View larger version (139K):
[in this window]
[in a new window]

  		FIG. 7. Validation of milk fat globule-EGF-factor 8 expression in human atherosclerotic coronary arteries. Top panels (A, B, and C; 4x magnification) show Ham-56, MFG-E8, and {alpha}-actin staining in serial sections from a human coronary artery. D and E are 40x images of Ham-56- and MFG-E8-stained areas selected in the dashed rectangle. F and G show the selected areas in the squares stained for MFG-E8 or {alpha}-actin (40x magnification). IH, intima hyperplasia; I, intima; M, media; Ad., adventitia; L, lumen. Note that a subset of macrophages and vascular SMCs are positive for MFG-E8 (E and F).

 
In addition to MFG-E8, we also validated annexin I expression in the atherosclerotic plaque by IHC. Fig. 8, A and B, shows a representative sample with anti-annexin I antibody staining lipid-loaded macrophages (foam cells) that are also positive for Ham-56 staining. The red arrows indicate the same cell in adjacent sections positive for both Ham-56 and annexin I. To further characterize the role of annexin I, we measured apoptotic nuclei by TUNEL staining in the plaque and evaluated whether the positive areas coincide with annexin I expression. In this analysis, we observed that apoptosis (Fig. 8, G and H) is occurring in annexin I-positive areas (Fig. 8, D and F) coinciding with foam cell-enriched areas within hyperplastic intima (Ham-56-positive areas; Fig. 8, C and E). In Fig. 8H shows how apoptotic cells (black arrows, brown nuclei) and normal foam cells (red arrows, blue nuclei) are distributed within the same area. These results indicate that annexin I is expressed in macrophage foam cells in the human atherosclerotic plaques. Furthermore we found that annexin I-positive areas also contained TUNEL-positive cells (Fig. 8, G and H). Annexin I expression was evaluated in 12 different samples, many of them showing foam cells and inflammation in the tunica adventitia. Seven of the 12 (58%) samples showed positive staining in the tunica intima and adventitia for annexin I.


Figure 8
View larger version (118K):
[in this window]
[in a new window]

  		FIG. 8. Validation of annexin I expression in human atherosclerotic coronary arteries. A and B (40x), co-localization of Ham-56- and annexin I-positive cells in human coronary atherosclerotic plaques. Adjacent sections were stained with annexin I or Ham-56 in the intima hyperplasia. Red arrows indicate the same cell in adjacent serial sections. C and D show Ham-56 and annexin I staining (4x). E and F are higher magnification (20x) pictures of the selected areas in C and D. G is the TUNEL assay of a serial section from the same sample shown in C and D. A higher magnification of the area selected in G is shown in H. TUNEL-positive cells are brown (black arrows), whereas the TUNEL-negative cells are blue (red arrows). IH, intima hyperplasia; M, media; Ad., adventitia; L, lumen.

 

   DISCUSSION
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Despite significant advancement in the treatment of coronary and cerebrovascular diseases, comprehensive understanding of the pathologic mechanisms is still lacking. To gain more comprehensive understanding of atherosclerosis progression, it is critical to better define the expressed proteins in the vessel wall. Proteins are the major effectors of most biological processes and are the most suitable molecules for use as biomarkers and risk factors as well as targets for disease treatment. Profiling of protein expression from pathological tissues provides a rough survey of the pathological state. Because proteins are the key effectors of function, the ability to efficiently utilize mass spectrometry to identify thousands of proteins in a single tissue and/or condition is extremely valuable. The major focus of this study was to identify proteins expressed within atherosclerotic lesions of coronary arteries that can be used as a platform for a better understanding of human atherosclerotic plaque development and progression. In the present study, we present a large scale protein profile of human atherosclerotic coronary arteries. The feasibility of DTP analysis was shown recently for prostate cancer (8). Despite the challenges of the multiple cell types and components of human atheroma lesions, we were able to show that DTP analysis is applicable to atherosclerotic coronary arteries even from archived paraffin blocks. Extracting proteins with a buffer containing SDS and separating the extracted proteins by 1D gel electrophoresis improved the number of identified proteins. In addition, when we utilized atherosclerotic coronary arteries preserved as frozen blocks instead of paraffin blocks, we observed that approximately twice the number of proteins can be identified by applying the DTP method (data not shown). Furthermore using the frozen samples in combination with SDS-PAGE, we were able to identify 558 individual proteins versus 225 proteins from the DTP paraffin block analysis, concluding that the analysis of frozen samples by the proposed methodology significantly increased the number of identified proteins. The absence of highly cross-linked proteins that limit extraction is a likely possibility for the improvement in protein identification seen in the frozen sections. In addition, resolving proteins by gel electrophoresis reduced the complexity of the samples, thus increasing protein identification by mass spectrometry.

Although we identified 806 proteins with high confidence, we did not identify cytokines and growth factors, which are expected to be present in lesions, even when we considered the single peptide hit proteins. Vascular endothelial growth factor (VEGF) as well as the VEGF receptors, fibroblast growth factor 2, vascular cell adhesion molecule, intercellular adhesion molecule, tumor necrosis factor {alpha}, TGF-ß, SDF1-{alpha}, interleukin 6, and other growth factors and cytokines could not be identified directly by this method. The absence of the above mentioned factors could be explained by one of the following reasons. First, abundance of these key molecules is likely to be much lower than the connective tissue proteins. Thus, there may be improvements that can be made for the identification of molecules present in low abundance. Second, many of these cytokines and receptors are post-translationally modified, most notably with advanced glycosylation, which may impact the peptide pool available for identification especially if a high threshold is set for multiple peptide identification. Third, most of these inflammatory cytokines are involved in plaque inflammation, instability, and rupture, whereas the coronary arteries in the present study were typically pathologically early, advanced stable, or healed plaques with organized thrombus. As none of our tissues apparently represent unstable plaques or acute rupture, the possibility of finding these cytokines at very high levels may be low. Finally evidence from our laboratory has shown that repeated analysis of the same sample significantly increased the total number of identified proteins.2 Based on this evidence, it is clear that the repeated analysis of each of the samples, by running them several times, may significantly improve total proteomics coverage for each sample and may lead to cytokine and growth factor detection. To test whether these cytokines and growth factors were present in the sample, we decided to apply MRM coupled to AQUA. By applying this selective methodology, we were able to detect and quantify TGF-ß and SDF1-{alpha}, confirming that these factors are present in the vessel wall but are undetectable by the less sensitive DTP method. These results suggest that MRM in association with AQUA is more sensitive for the targeted identification and quantification of low abundance proteins in histological tissue sections.

As we expected based on the literature, by mass spectrometry-based sequencing, we were able to confirm the presence of proteins such as extracellular matrix proteins that are involved in atherosclerosis progression. The increased expression of these proteins is associated with the proliferation of SMCs, a phenotypic change, and the migration from the tunica media to the intima (24–27). On the other hand, the overexpression of this group of proteins represents a positive feedback on the proliferation, migration, and changes in SMC phenotype that occurs during the atherosclerosis progression (27). The other group of proteins that we were able to confirm in the atherosclerotic vessel wall is the one represented by lipoproteins (Supplemental Table 7). This was also expected because modified lipoproteins accumulate in atherosclerotic lesions, a phenomenon partially due to the increased levels of extracellular matrix proteins (28, 29). The identification of proteins that are known to have an active role during atherosclerosis development validates our method and supports the utilization of this type of approach for the identification of novel proteins involved in the development of the disease.

Among the selected proteins from the general list (Supplemental Table 7), PEDF, periostin, MFG-E8, and annexin I were validated by IHC. While this manuscript was in preparation PEDF expression was reported in the atherosclerotic plaque in the aorta and coronary arteries (30). Mass spectrometry detection and IHC staining observed in our study further confirmed the presence of PEDF in the human plaque, suggesting that the factor might play a role in the evolution of the disease. Supporting this idea, it was reported that PEDF is expressed in vitro in a model of differentiated macrophages when these cells are exposed to oxidized low density lipoprotein (31). It has also been shown that PEDF is expressed during embryogenesis particularly in association with the developing bone matrix (32). In the same study the authors showed that osteoblasts and to a lesser extent osteoclasts express and secret PEDF (32). This evidence suggests that PEDF could be participating in extracellular matrix remodeling, and by doing this, it might be involved in controlling calcification, cell migration, and/or angiogenesis. On the other hand we found PEDF expression predominantly in two areas: macrophage-derived foam cell-rich areas and inflammatory areas in the intima and in the adventitia. This indicates a probable role of PEDF in inflammatory cells migration and proliferation. In support of this idea, exposure to PEDF induces the release of proinflammatory factors such as interleukin 1ß; interleukin 6; macrophage inflammatory proteins 1, 2, and 3 {alpha}; and tumor necrosis factor {alpha} in isolated microglia, astrocytes, and cerebellar granule neurons (33–36). Similarly the presence of PEDF in the inflammatory areas of human coronary atherosclerotic plaques suggests that this factor may have an autocrine and/or paracrine effect on inflammatory cells of the plaques. Although all this evidence strongly suggests that PEDF is involved in the atherosclerotic process, further experiments in animal models are needed to unravel the specific role of this factor in atherogenesis.

From the group of extracellular matrix proteins, periostin was selected for further characterization. The connection between periostin and atherosclerosis is supported by in vivo experiments. Lindner et al. (15) showed that in the rat carotid balloon injury periostin mRNA is one of the most strongly up-regulated factors in SMCs during neointima formation. In addition, it was shown that overexpression of this protein induces cell migration, and this effect is blocked by periostin antibody pretreatment. On the other hand it has been shown that periostin is up-regulated in rat lung and in isolated pulmonary arterial SMCs in response to hypoxic stress (37), a situation likely to occur during atherosclerosis progression. Finally periostin expression has been associated with angiogenesis, and its expression is increased in human breast cancer (38). This study shows that different cell lines overexpressing periostin induce tumor growth and angiogenesis of xenografts in mice (38). In addition, in a co-culture system of tumor cells overexpressing periostin and human microvascular endothelial cells, it was shown that the protein induces cell migration and proliferation. Supporting its role in angiogenesis, the authors showed that exposure to periostin increases VEGF receptor expression in human microvascular endothelial cells (38). Although these reports implicate periostin in pathological conditions in vivo, no information is available regarding periostin expression in human coronary atherosclerotic plaque. In the present study, we showed periostin expression in several different types of lesions. Periostin has been identified extensively by mass spectrometry in about 90% of the analyzed samples with 40% coverage based on the percentage of identified amino acids. From our IHC data, we have confirmed the presence of periostin in human atherosclerotic plaques specifically in the intima, preatheroma regions, and extracellular matrix of more advanced lesions presenting calcification. However, published data (15) suggest that periostin may act as a potent migratory stimulus in the neointima; our analysis of human lesions validates the presence and association of periostin in human atherosclerosis development.

Finally we also analyzed two proteins related to the phagocytosis of apoptotic cells present in the plaque. It is known that apoptosis occurs during atherosclerosis development (16, 39, 40), and it has been associated with the instability of the plaque (18, 41, 42). On the other hand, phagocytosis of apoptotic cells is a critical aspect of controlling inflammation that greatly contributes to tissue homeostasis. By mass spectrometry-based protein identification we found several proteins that have been shown to be involved in the phagocytosis of apoptotic cells. We chose to validate two of the phagocytosis ligands, MFG-E8 and annexin I, by IHC. We found MFG-E8 expression by IHC in the atherosclerotic plaque. An anti-MFG-E8 antibody stained strongly the tunica intima. Interestingly MFG-E8 is also expressed strongly in the subset of SMCs in the intima, indicating that not only macrophages express this molecule (Fig. 7 and Supplemental Fig. S6). In regard to this, Geng et al. (39) have shown that SMCs in the intima of atherosclerotic samples express Fas and die by apoptosis. During apoptotic cell engulfment, MFG-E8 is secreted by macrophages and binds to the phosphatidylserine at the surface of apoptotic cells. Assuming this is the ongoing sequence of events, we think that the MFG-E8 seen in the plaque is attached to the surface of cells that have died by apoptosis and need to be removed by phagocytosis. Although the role of MFG-E8 in the phagocytosis of apoptotic cells has been well documented (44), whether this protein is involved in atherosclerosis needs to be further investigated.

Our results suggest that annexin I is expressed in macrophages present in the tunica intima. Furthermore these macrophages present a foam cell phenotype, and they are positive for Ham-56 antibody staining. There is strong evidence demonstrating the role of annexin I in the phagocytosis of apoptotic cells (45). During apoptosis, cells expose annexin I at the surface, and the molecule acts as an "eat me signal" that contributes toward recognition and subsequent phagocytosis of the apoptotic cells (45). On the other hand, it has been shown that annexin I can be expressed by macrophages during apoptotic T lymphocyte clearance (46). Although these studies might explain the presence of annexin I in the plaque, we cannot rule out the possibility that the cross-reaction of the foam cell with anti-annexin I antibody is due to the contribution from the phagocytosis of apoptotic cells. In an attempt to clarify this, we analyzed apoptosis in the plaque. We found that Ham-56-positive areas (macrophages) presenting foam cells are also positive for annexin I staining (Fig. 8, C, D, E, and F). In addition, the TUNEL assay showed high specificity for overlapping areas in serial sections. These results support the idea that annexin I participates in the engulfment of apoptotic bodies present in the plaque. The presence of two known engulfment ligands in the plaque suggests that engulfment of apoptotic cells is likely to be a factor involved in the development and progression of atherosclerosis.

This is the first study providing large scale protein identification of human coronary arteries and coronary atherosclerotic plaques that is freely available in a searchable format for the larger scientific community. We performed the present feasibility study to assess the practical limitations associated with analysis of coronary arteries and atherosclerotic plaques. Our study demonstrates that we were able to identify a large number of high abundance proteins expressed in the human coronary arteries. Four of these biologically interesting proteins were validated by IHC. Furthermore we were able to combine the LCM method with the DTP method, paving the way for future investigations where the proteome from a specific cell type can be enriched and identified. Moreover using the AQUA method, we were able to demonstrate the presence of low abundance cytokine/growth factor in the human coronary arteries. We anticipate that the proteomics methodologies we have utilized will be embraced in the future for detection of key protein molecules in clinically relevant human tissues. This information will be useful for basic understanding of disease processes as well as for clinical applications such as diagnosis and early detection of pathological conditions.


   ACKNOWLEDGMENTS
 
We thank Linfeng Wu, Michael Fong, and other members of the Han laboratory for helpful discussion.


  FOOTNOTES
 
Received, July 14, 2006, and in revised form, February 27, 2007.

Published, MCP Papers in Press, March 5, 2007, DOI 10.1074/mcp.M600259-MCP200

1 The abbreviations used are: SMC, smooth muscle cell; AQUA, absolute quantification of abundance; DAB, diaminobenzidine; DTP, direct tissue proteomics; H&E, hematoxylin and eosin; HFBA, heptafluorobutyric acid; IHC, immunohistochemistry; LCM, laser capture microdissection; MFG-E8, milk fat globule-EGF-factor 8; EGF, epidermal growth factor; MRM, multiple reaction monitoring; PDGF-ß, platelet-derived growth factor ß; PEDF, pigment epithelium-derived factor; SDF1-{alpha}, stromal cell-derived factor 1 {alpha}; TGF-ß, transforming growth factor ß; TUNEL, terminal deoxynucleotidyltransferase dUTP nick-end labeling; VEGF, vascular endothelial growth factor; 1D, one-dimensional. Back

2 L. Wu, S. I. Hwang, K. Rezaul, L. J. Lu, V. Mayya, M. Girstein, J. K. Eng, D. H. Lundgren, and D. K. Han, in press. Back

* This work was supported by National Institutes of Health Grants HL67569 and HL70694. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

S The on-line version of this article (available at http://www.mcponline.org) contains supplemental material. Back

§ Both authors contributed equally to this work. Back

{ddagger}{ddagger} To whom correspondence should be addressed: Dept. of Cell Biology, Center for Vascular Biology, University of Connecticut School of Medicine, 263 Farmington Ave., Farmington, CT 06030. Tel.: 860-679-2444; Fax: 860-679-1201; E-mail: han{at}nso.uchc.edu


   REFERENCES
TOP
 ABSTRACT
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Aebersold, R., and Mann, M. (2003) Mass spectrometry-based proteomics. Nature 422, 198 –207[CrossRef][Medline]

  2. Florens, L., Washburn, M. P., Raine, J. D., Anthony, R. M., Grainger, M., Haynes, J. D., Moch, J. K., Muster, N., Sacci, J. B., Tabb, D. L., Witney, A. A., Wolters, D., Wu, Y., Gardner, M. J., Holder, A. A., Sinden, R. E., Yates, J. R., and Carucci, D. J. (2002) A proteomic view of the Plasmodium falciparum life cycle. Nature 419, 520 –526[CrossRef][Medline]

  3. Koller, A., Washburn, M. P., Lange, B. M., Andon, N. L., Deciu, C., Haynes, P. A., Hays, L., Schieltz, D., Ulaszek, R., Wei, J., Wolters, D., and Yates, J. R., III (2002) Proteomic survey of metabolic pathways in rice. Proc. Natl. Acad. Sci. U. S. A. 99, 11969 –11974[Abstract/Free Full Text]

  4. Washburn, M. P., Wolters, D., and Yates, J. R., III (2001) Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19, 242 –247[CrossRef][Medline]

  5. Wittliff, J. L., and Erlander, M. G. (2002) Laser capture microdissection and its applications in genomics and proteomics. Methods Enzymol 356, 12 –25[Medline]

  6. Marko-Varga, G., Berglund, M., Malmstrom, J., Lindberg, H., and Fehniger, T. E. (2003) Targeting hepatocytes from liver tissue by laser capture microdissection and proteomics expression profiling. Electrophoresis 24, 3800 –3805[CrossRef][Medline]

  7. Li, C., Hong, Y., Tan, Y. X., Zhou, H., Ai, J. H., Li, S. J., Zhang, L., Xia, Q. C., Wu, J. R., Wang, H. Y., and Zeng, R. (2004) Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 3, 399 –409[Abstract/Free Full Text]

  8. Hwang, S. I., Thumar, J., Lundgren, D. H., Rezaul, K., Mayya, V., Wu, L., Eng, J., Wright, M. E., and Han, D. K. (2007) Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues. Oncogene 26, 65 –76[CrossRef][Medline]

  9. Rezaul, K., Wu, L., Mayya, V., Hwang, S. I., and Han, D. (2005) A systematic characterization of mitochondrial proteome from human T leukemia cells. Mol. Cell. Proteomics 4, 169 –181[Abstract/Free Full Text]

  10. Eng, J. K., McCormark, A. L., and Yates, J. R., III. (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein data base. J. Am. Soc. Mass Spectrom. 5, 976 –989[CrossRef]

  11. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., and Gygi, S. P. (2003) Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U. S. A. 100, 6940 –6945[Abstract/Free Full Text]

  12. Mayya, V., Rezaul, K., Wu, L., Fong, M. B., and Han, D. K. (2006) Absolute quantification of multi-site phosphorylation by selective reaction monitoring mass spectrometry: determination of inhibitory phosphorylation status of cyclin dependent kinases. Mol. Cell. Proteomics 5, 1146 –1157[Abstract/Free Full Text]

  13. Biemann, K. (1990) Sequencing of peptides by tandem mass spectrometry and high-energy collision-induced dissociation. Methods Enzymol. 193, 455 –479[Medline]

  14. Steele, F. R., Chader, G. J., Johnson, L. V., and Tombran-Tink, J. (1993) Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc. Natl. Acad. Sci. U. S. A. 90, 1526 –1530[Abstract/Free Full Text]

  15. Lindner, V., Wang, Q., Conley, B. A., Friesel, R. E., and Vary, C. P. (2005) Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler. Thromb. Vasc. Biol. 25, 77 –83[Abstract/Free Full Text]

  16. Han, D. K., Haudenschild, C. C., Hong, M. K., Tinkle, B. T., Leon, M. B., and Liau, G. (1995) Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am. J. Pathol. 147, 267 –277[Abstract]

  17. Bennett, M. R. (1999) Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41, 361 –368[Abstract/Free Full Text]

  18. Kolodgie, F. D., Narula, J., Burke, A. P., Haider, N., Farb, A., Hui-Liang, Y., Smialek, J., and Virmani, R. (2000) Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. J. Pathol. 157, 1259 –1268[Abstract/Free Full Text]

  19. Savill, J., and Fadok, V. (2000) Corpse clearance defines the meaning of cell death. Nature 407, 784 –788[CrossRef][Medline]

  20. Lauber, K., Blumenthal, S. G., Waibel, M., and Wesselborg, S. (2004) Clearance of apoptotic cells: getting rid of the corpses. Mol. Cell 14, 277 –287[CrossRef][Medline]

  21. Schaub, F. J., Han, D. K., Liles, W. C., Adams, L. D., Coats, S. A., Ramachandran, R. K., Seifert, R. A., Schwartz, S. M., and Bowen-Pope, D. F. (2000) Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat. Med. 6, 790 –796[CrossRef][Medline]

  22. Schrijvers, D. M., De Meyer, G. R., Kockx, M. M., Herman, A. G., and Martinet, W. (2005) Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256 –1261[Abstract/Free Full Text]

  23. Khan, M., Pelengaris, S., Cooper, M., Smith, C., Evan, G., and Betteridge, J. (2003) Oxidised lipoproteins may promote inflammation through the selective delay of engulfment but not binding of apoptotic cells by macrophages. Atherosclerosis 171, 21 –29[CrossRef][Medline]

  24. Chamley-Campbell, J. H., Campbell, G. R., and Ross, R. (1981) Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J. Cell Biol. 89, 379 –383[Abstract/Free Full Text]

  25. Ang, A. H., Tachas, G., Campbell, J. H., Bateman, J. F., and Campbell, G. R. (1990) Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with phenotype. Biochem. J. 265, 461 –469[Medline]

  26. Merrilees, M. J., Campbell, J. H., Spanidis, E., and Campbell, G. R. (1990) Glycosaminoglycan synthesis by smooth muscle cells of differing phenotype and their response to endothelial cell conditioned medium. Atherosclerosis 81, 245 –254[CrossRef][Medline]

  27. Evanko, S. P., Angello, J. C., and Wight, T. N. (1999) Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1004 –1013[Abstract/Free Full Text]

  28. O'Brien, K. D., Olin, K. L., Alpers, C. E., Chiu, W., Ferguson, M., Hudkins, K., Wight, T. N., and Chait, A. (1998) Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 98, 519 –527[Abstract/Free Full Text]

  29. Olsson, U., Camejo, G., and Bondjers, G. (1993) Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin 6-sulfate: effects of the lipid environment. Biochemistry 32, 1858 –1865[CrossRef][Medline]

  30. Baba, H., Yonemitsu, Y., Nakano, T., Onimaru, M., Miyazaki, M., Ikeda, Y., Sumiyoshi, S., Ueda, Y., Hasegawa, M., Yoshino, I., Maehara, Y., and Sueishi, K. (2005) Cytoplasmic expression and extracellular deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 25, 1938 –1944[Abstract/Free Full Text]

  31. Fach, E. M., Garulacan, L. A., Gao, J., Xiao, Q., Storm, S. M., Dubaquie, Y. P., Hefta, S. A., and Opiteck, G. J. (2004) In vitro biomarker discovery for atherosclerosis by proteomics. Mol. Cell. Proteomics 3, 1200 –1210[Abstract/Free Full Text]

  32. Tombran-Tink, J., and Barnstable, C. J. (2004) Osteoblasts and osteoclasts express PEDF, VEGF-A isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix remodeling in the bone. Biochem. Biophys. Res. Commun. 316, 573 –579[CrossRef][Medline]

  33. Yabe, T., Herbert, J. T., Takanohashi, A., and Schwartz, J. P. (2004) Treatment of cerebellar granule cell neurons with the neurotrophic factor pigment epithelium-derived factor in vitro enhances expression of other neurotrophic factors as well as cytokines and chemokines. J. Neurosci. Res. 77, 642 –652[CrossRef][Medline]

  34. Yabe, T., Sanagi, T., Schwartz, J. P., and Yamada, H. (2005) Pigment epithelium-derived factor induces pro-inflammatory genes in neonatal astrocytes through activation of NF-{kappa}B and CREB. Glia 50, 223 –234[CrossRef][Medline]

  35. Sanagi, T., Yabe, T., and Yamada, H. (2005) The regulation of pro-inflammatory gene expression induced by pigment epithelium-derived factor in rat cultured microglial cells. Neurosci. Lett. 380, 105 –110[CrossRef][Medline]

  36. Takanohashi, A., Yabe, T., and Schwartz, J. P. (2005) Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia 51, 266 –278[CrossRef][Medline]

  37. Li, P., Oparil, S., Feng, W., and Chen, Y. F. (2004) Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J. Appl. Physiol. 97, 1550 –1558; discussion 1549[Abstract/Free Full Text]

  38. Sao, R., Bao, S., Bai, X., Blanchette, C., Anderson, R. M., Dang, T., Gishizky, M. L., Marks, J. R., and Wang, X. F. (2004) Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 24, 3992 –4003[Abstract/Free Full Text]

  39. Geng, Y. J., Henderson, L. E., Levesque, E. B., Muszynski, M., and Libby, P. (1997) Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 17, 2200 –2208[Abstract/Free Full Text]

  40. Geng, Y. J., and Libby, P. (1995) Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol. 147, 251 –266[Abstract]

  41. Mallat, Z., Hugel, B., Ohan, J., Leseche, G., Freyssinet, J. M., and Tedgui, A. (1999) Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99, 348 –353[Abstract/Free Full Text]

  42. Chen, F., Eriksson, P., Kimura, T., Herzfeld, I., and Valen, G. (2005) Apoptosis and angiogenesis are induced in the unstable coronary atherosclerotic plaque. Coron. Artery Dis. 16, 191 –197[CrossRef][Medline]

  43. Hanayama, R., Tanaka, M., Miwa, K., Shinohara, A., Iwamatsu, A., and Nagata, S. (2002) Identification of a factor that links apoptotic cells to phagocytes. Nature 417, 182 –187[CrossRef][Medline]

  44. Hanayama, R., Tanaka, M., Miyasaka, K., Aozasa, K., Koike, M., Uchiyama, Y., and Nagata, S. (2004) Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304, 1147 –1150[Abstract/Free Full Text]

  45. Arur, S., Uche, U. E., Rezaul, K., Fong, M., Scranton, V., Cowan, A. E., Mohler, W., and Han, D. K. (2003) Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev. Cell 4, 587 –598[CrossRef][Medline]

  46. Fan, X., Krahling, S., Smith, D., Williamson, P., and Schlegel, R. A. (2004) Macrophage surface expression of annexins I and II in the phagocytosis of apoptotic lymphocytes. Mol. Biol. Cell 15, 2863 –2872[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Circ. Res.Home page
Z. Fu, M. Wang, M. Gucek, J. Zhang, J. Wu, L. Jiang, R. E. Monticone, B. Khazan, R. Telljohann, J. Mattison, et al.
Milk Fat Globule Protein Epidermal Growth Factor-8: A Pivotal Relay Element Within the Angiotensin II and Monocyte Chemoattractant Protein-1 Signaling Cascade Mediating Vascular Smooth Muscle Cells Invasion
Circ. Res., June 19, 2009; 104(12): 1337 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. V. G. Edwards, M. Y. White, and S. J. Cordwell
The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M600259-MCP200v1
M600259-MCP200v2
6/6/1088    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Glossary
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bagnato, C.
Right arrow Articles by Han, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bagnato, C.
Right arrow Articles by Han, D. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Advertisement
spacer
Advertisement
Advertisement